Automate Your Wheel Strategy on TEM
With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEM
- Rev/Share 6.3177
- Book/Share 2.9028
- PB 22.7094
- Debt/Equity 2.6305
- CurrentRatio 3.2755
- ROIC -0.1014
- MktCap 11302917493.0
- FreeCF/Share -1.4182
- PFCF -45.5572
- PE -56.5656
- Debt/Assets 0.5855
- DivYield 0
- ROE -0.6796
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | TEM | Morgan Stanley | -- | Overweight | -- | $85 | Dec. 2, 2025 |
| Downgrade | TEM | TD Cowen | Buy | Hold | -- | $88 | Oct. 21, 2025 |
| Initiation | TEM | Canaccord Genuity | -- | Buy | -- | $110 | Oct. 20, 2025 |
| Initiation | TEM | H.C. Wainwright | -- | Buy | -- | $90 | Sept. 2, 2025 |
| Initiation | TEM | BTIG Research | -- | Buy | -- | $60 | April 21, 2025 |
| Downgrade | TEM | JP Morgan | Overweight | Neutral | $50 | $55 | Feb. 25, 2025 |
| Downgrade | TEM | William Blair | Outperform | Market Perform | -- | -- | Feb. 12, 2025 |
| Resumed | TEM | TD Cowen | -- | Buy | $58 | $74 | Feb. 5, 2025 |
| Initiation | TEM | Wolfe Research | -- | Outperform | -- | $60 | Dec. 13, 2024 |
| Initiation | TEM | Guggenheim | -- | Buy | -- | $74 | Dec. 9, 2024 |
News
Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI posts first positive adjusted EBITDA as genomics testing accelerates and data bookings broaden. Zacks Rank #3 (Hold) with mixed Style Scores.
Read More
Tempus AI: Plenty Of Growth Catalysts Ahead, Grab It While It's Down
Published: December 16, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI remains a Buy after a market-driven correction, with operational performance and partnerships strengthening the long-term thesis. TEM's organic revenue grew 28% y/y, gross margins improved 450bps to 63%, and liquidity increased to $760M, supporting continued investment and debt service. Management targets sustainable 25% annual genomics growth through 2028, with high-margin Data & Insights segment poised for outsized profitability.
Read More
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
Read More
3 MedTech Stocks Poised to Gain in 2026 From the AI Boom
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
AI is reshaping MedTech, and Stryker, Tempus AI and GE HealthCare are emerging as key players leveraging AI across surgery, diagnostics and imaging.
Read More
Tempus AI Near $75 Target? Valuation, Upside and Risks
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
Read More
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
Read More
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.
Read More
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
Read More
Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition.
Read More
Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?
Published: December 05, 2025 by: The Motley Fool
Sentiment: Positive
Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies.
Read More
Why Is Tempus (TEM) Down 8.9% Since Last Earnings Report?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Tempus (TEM) reported earnings 30 days ago. What's next for the stock?
Read More
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Read More
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET. The live webcast will be available through the events page of Tempus' Investor Relations website or by clicking the following link: https://ev.
Read More
How Did Tempus AI Power Its Move to Positive EBITDA in Q3?
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.
Read More
TEM Continues to Strengthen Its Genomics Leadership With New Products
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.
Read More
Tempus AI, Inc. (TEM) Presents at Stifel 2025 Healthcare Conference Transcript
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. ( TEM ) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division Okay. Welcome back, everyone, to the 2025 Stifel Healthcare Conference.
Read More
Tempus AI: Great Buying Opportunity On Recent Weakness
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid performance in both Genomics and Data/Services segments, with high visibility into future growth. The recent stock pullback, driven by high expectations, presents an attractive entry point for long-term investors willing to accept volatility and premium valuation.
Read More
Tempus AI: Volatility Equates to Opportunity in AI Leader
Published: November 06, 2025 by: MarketBeat
Sentiment: Positive
Tempus AI's NASDAQ: TEM stock price pulled back in early November following its Q3 release, aligning with broader market action and opening a buying opportunity for investors. The primary concern is the valuation, which is admittedly high relative to its current-year outlook.
Read More
TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline following the results.
Read More
This AI Health Stock is Up Over 150% This Year—and It's Not Slowing Down
Published: October 31, 2025 by: 24/7 Wall Street
Sentiment: Positive
Tempus AI (NASDAQ:TEM) isn't an AI stock that immediately comes to mind when one thinks of machine-learning-driven technological innovators with disruptive potential.
Read More
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.
Read More
Tempus to Report Third Quarter 2025 Financial Results on November 4
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Altern.
Read More
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.
Read More
Tempus AI Fuels Growth Through Strategic Biotech Collaborations
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
Read More
Tempus AI Hits $100—Are Shares Due for a Pullback?
Published: October 15, 2025 by: MarketBeat
Sentiment: Positive
Tempus AI NASDAQ: TEM has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on Monday, Oct. 13.
Read More
TEM Expands Partnership With Northwestern Medicine Amid AI Boom
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.
Read More
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
Read More
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
Published: October 01, 2025 by: Business Wire
Sentiment: Neutral
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.
Read More
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to Grand View Research. Tempus AI TEM and Illumina ILMN are two key players with significant presence in this market.
Read More
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.
Read More
About Tempus AI, Inc. (TEM)
- IPO Date 2024-06-14
- Website https://www.tempus.com
- Industry Medical - Healthcare Information Services
- CEO Eric Lefkofsky
- Employees 2400